• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α1抗胰蛋白酶缺乏症患者肺功能损害的进展速率

Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.

作者信息

Dawkins P A, Dawkins C L, Wood A M, Nightingale P G, Stockley J A, Stockley R A

机构信息

Lung Investigation Unit, UniversityHospital Birmingham and University of Birmingham, Birmingham, UK.

出版信息

Eur Respir J. 2009 Jun;33(6):1338-44. doi: 10.1183/09031936.00061208. Epub 2009 Jan 22.

DOI:10.1183/09031936.00061208
PMID:19164359
Abstract

The aim of the present study was to identify alpha(1)-antitrypsin (alpha(1)-AT)-deficient patients who had rapidly progressive disease. PiZ patients (n = 101) underwent annual lung function measurements over a 3-yr period, and the results were related to factors that may influence decline. The mean annual decline in forced expiratory volume in 1 s (FEV(1)) was 49.9 mL. The greatest FEV(1) decline occurred in the moderate severity group (FEV(1) 50-80% of the predicted value), with a mean annual decline of 90.1 mL, compared with 8.1 mL in the very severe group (FEV(1) <30% pred). However, annual decline in transfer coefficient of the lung for carbon monoxide (K(CO)) was greatest in the severe and very severe groups. When the whole group was divided into tertiles of FEV(1) decline, the fast tertile compared with the slow tertile had more patients with bronchodilator reversibility (BDR) (73 versus 41%; p = 0.010), more males (79 versus 56%; p = 0.048) and lower body mass index (BMI) (24.0 versus 26.1; p = 0.042). Logistic regression analyses confirmed that FEV(1) decline was independently associated with BMI, BDR, exacerbation rate and high physical component 36-item short-form health survey scores. In PiZ alpha(1)-AT-deficient patients, FEV(1) decline was greatest in moderate disease, unlike K(CO) decline, which was greatest in severe disease. The FEV(1) decline showed associations with BDR, BMI, sex and exacerbation rate.

摘要

本研究的目的是识别患有快速进展性疾病的α1抗胰蛋白酶(α1-AT)缺乏患者。101名PiZ型患者在3年期间每年进行肺功能测量,结果与可能影响肺功能下降的因素相关。第1秒用力呼气量(FEV1)的年平均下降量为49.9 mL。FEV1下降最大的发生在中度严重程度组(FEV1为预测值的50%-80%),年平均下降量为90.1 mL,而在极重度组(FEV1<预测值的30%)为8.1 mL。然而,一氧化碳肺转移系数(KCO)的年下降量在重度和极重度组中最大。当将整个组按FEV1下降的三分位数划分时,与下降较慢的三分位数相比,下降较快的三分位数中有更多的患者具有支气管扩张剂可逆性(BDR)(73%对41%;p = 0.010)、更多男性(79%对56%;p = 0.048)和更低的体重指数(BMI)(24.0对26.1;p = 0.042)。逻辑回归分析证实,FEV1下降与BMI、BDR、急性加重率和健康调查简表36项身体成分高分独立相关。在PiZ型α1-AT缺乏患者中,与KCO下降不同,FEV1下降在中度疾病中最大,而KCO下降在重度疾病中最大。FEV1下降与BDR、BMI、性别和急性加重率相关。

相似文献

1
Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.α1抗胰蛋白酶缺乏症患者肺功能损害的进展速率
Eur Respir J. 2009 Jun;33(6):1338-44. doi: 10.1183/09031936.00061208. Epub 2009 Jan 22.
2
Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV in individuals with PiZZ alpha-1-antitrypsin deficiency.对于PiZZ型α-1抗胰蛋白酶缺乏症患者,病情加重和戒烟时长与每年的第一秒用力呼气容积(FEV)损失相关。
Respir Med. 2017 Aug;129:8-15. doi: 10.1016/j.rmed.2017.05.011. Epub 2017 May 24.
3
Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.α1抗胰蛋白酶缺乏症患者生理、放射学和健康状况测量的纵向变化及其相关衰退因素
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1805-9. doi: 10.1164/ajrccm.164.10.2106036.
4
Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.慢性阻塞性肺疾病的肺功能和临床表型的年度变化。
Am J Respir Crit Care Med. 2012 Jan 1;185(1):44-52. doi: 10.1164/rccm.201106-0992OC.
5
Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?α-1抗胰蛋白酶缺乏症患者的个体化肺功能趋势:为提供以患者为中心的管理是否需要耐心?
Int J Chron Obstruct Pulmon Dis. 2016 Aug 1;11:1745-56. doi: 10.2147/COPD.S111508. eCollection 2016.
6
Decline in FEV and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.严重的α-1 抗胰蛋白酶缺乏症个体的 FEV 下降和住院加重。
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1075-1083. doi: 10.2147/COPD.S195847. eCollection 2019.
7
Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.α1-抗胰蛋白酶缺乏型 COPD 患者加重频率、持续时间与肺功能和肺密度基线间的关系。
Int J Chron Obstruct Pulmon Dis. 2012;7:789-96. doi: 10.2147/COPD.S31797. Epub 2012 Nov 27.
8
Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.α1-抗胰蛋白酶缺乏症患者健康状况的年度变化与计算机断层扫描得出的肺密度之间的相关性。
Thorax. 2003 Dec;58(12):1027-30. doi: 10.1136/thorax.58.12.1027.
9
The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study.慢性阻塞性肺疾病中快速的 FEV1 下降与主要的肺气肿有关:一项纵向研究。
COPD. 2013 Feb;10(1):55-61. doi: 10.3109/15412555.2012.727920. Epub 2012 Dec 28.
10
Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.α1-蛋白酶抑制剂缺乏症患者在静脉注射α1-蛋白酶抑制剂治疗前及治疗期间的纵向随访。
Chest. 2001 Mar;119(3):737-44. doi: 10.1378/chest.119.3.737.

引用本文的文献

1
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society.CT密度测定法在临床试验中用于评估肺气肿:来自弗莱施纳学会的立场文件。
Am J Respir Crit Care Med. 2025 Mar 24;211(5):709-28. doi: 10.1164/rccm.202410-2012SO.
2
Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency.α-1抗胰蛋白酶缺乏症的诊断和治疗建议。
J Bras Pneumol. 2024 Dec 6;50(5):e20240235. doi: 10.36416/1806-3756/e20240235. eCollection 2024.
3
Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status.
根据吸烟状况分析慢性阻塞性肺疾病的临床特征
Tuberc Respir Dis (Seoul). 2025 Jan;88(1):14-25. doi: 10.4046/trd.2024.0060. Epub 2024 Oct 30.
4
Antitrypsin deficiency: still more to learn about the lung after 60 years.抗胰蛋白酶缺乏症:60年后肺部仍有更多有待了解之处。
ERJ Open Res. 2024 Jul 22;10(4). doi: 10.1183/23120541.00139-2024. eCollection 2024 Jul.
5
Assessing the efficacy of Alpha-Proteinase inhibitor (human) augmentation therapy for Alpha-Antitrypsin deficiency - Related emphysema: Challenges and opportunities.评估α-蛋白酶抑制剂(人)增强疗法对α-抗胰蛋白酶缺乏症相关肺气肿的疗效:挑战与机遇。
Heliyon. 2024 May 23;10(11):e31183. doi: 10.1016/j.heliyon.2024.e31183. eCollection 2024 Jun 15.
6
Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.严重α-1 抗胰蛋白酶缺乏症的增强治疗可改善生存,与肺功能下降脱钩——一项多国登记分析。
Am J Respir Crit Care Med. 2023 Nov 1;208(9):964-974. doi: 10.1164/rccm.202305-0863OC.
7
Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry.α-1 抗胰蛋白酶缺乏个体的临床和功能特征:EARCO 国际登记处。
Respir Res. 2022 Dec 16;23(1):352. doi: 10.1186/s12931-022-02275-4.
8
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews.与α-1 抗胰蛋白酶缺乏症相关的疾病负担:系统和结构化文献回顾。
Eur Respir Rev. 2022 Mar 23;31(163). doi: 10.1183/16000617.0262-2021. Print 2022 Mar 31.
9
Long-term effect of α-antitrypsin augmentation therapy on the decline of FEV in deficient patients: an analysis of the AIR database.α-抗胰蛋白酶补充疗法对缺陷患者第一秒用力呼气容积下降的长期影响:AIR数据库分析
ERJ Open Res. 2021 Aug 23;7(3). doi: 10.1183/23120541.00194-2021. eCollection 2021 Jul.
10
Pleiotropic associations of heterozygosity for the Z allele in the UK Biobank.英国生物银行中Z等位基因杂合性的多效性关联。
ERJ Open Res. 2021 May 10;7(2). doi: 10.1183/23120541.00049-2021. eCollection 2021 Apr.